

10. (Amended) The method of claim 7, wherein said trefoil protein is spasmolytic peptide (SP).

11. (Amended) The method of claim 7, wherein said trefoil protein is pS2.

REMARKS

The Invention

This invention provides methods for treating a disorder or lesion of the eye by administering an intestinal trefoil peptide.

Support for Amendments

Support for the amendments to claims 1 and 7 is found in the specification at page 13, lines 21-23. No new matter is introduced by these amendments.

A “marked up” version of the claims showing the changes made and an appendix of the claims as pending are attached.

The Office Action

Claims 1-12 are pending in this application. Claims 1-12 stand rejected under 35 U.S.C. § 112, first paragraph, for a lack of enablement, and under 35 U.S.C. § 112, second paragraph, for indefiniteness. Claims 1, 2, 6, 7, and 12 are further rejected under 35 U.S.C. § 102(b) as being anticipated by U.S. Patent No. 5,703,047.

Rejections Under 35 U.S.C. § 112, first paragraph

Claims 1-12 are rejected under 35 U.S.C. § 112, first paragraph, for lack of enablement. Specifically, the Examiner states that, while enabling for a method of enhancing corneal epithelial wound healing using ITF, the specification does not enable